沃尔登斯特罗姆宏球蛋白血症:2025年关于诊断,风险分层和管理的更新
1Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
American journal of hematology
|March 17, 2025
概括
沃尔登斯特罗姆巨型球蛋白血症 (WM) 是通过IgM单克隆蛋白和克隆细胞来诊断的. 风险分层使用临床因素,治疗包括化学免疫疗法或布鲁顿氨酸激酶抑制剂,优先考虑降低毒性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 罕见疾病 罕见疾病
背景情况:
- 沃尔登斯特罗姆巨型球蛋白病 (WM) 是一种罕见的淋巴细胞性淋巴瘤,其特征是免疫球蛋白M (IgM) 单克隆蛋白.
- 临床表现包括贫血,血小板缺血,肝炎,淋巴腺病和潜在的高粘度综合征.
研究的目的:
- 提供沃尔登斯特罗姆巨型球蛋白血症诊断,风险分层和治疗方法的概述.
- 突出目前的治疗策略和耐火性疾病的管理.
主要方法:
- 通过IgM单克隆蛋白和骨髓中≥10%的克隆性淋巴细胞细胞证实了诊断.
- 在90%以上的患者中检测到MYD88 L265P突变.
- 基于年龄,白蛋白,血红蛋白,血小板,β2微型血红蛋白,LDH和IgM水平的风险分层.
主要成果:
- 风险分层确定了患者结果的关键预后因素.
- 第一线治疗建议包括化学免疫疗法或共价布鲁顿氨酸激酶抑制剂.
- 组合治疗方案优于rituximab单一治疗.
结论:
- 几种药物在复发性WM中表现出活性,包括博尔特佐米布,达穆斯丁和venetoclax.
- 考虑到WM的自然历史,尽量减少治疗毒性至关重要.
- 大多数患者死于与WM无关的原因.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.1K
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
20.9K
相关概念视频
Therapeutic Drug Monitoring: Overview and Classification
642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Rheumatic Heart Disease III: Medical Management
544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Nephrotic Syndrome II : Assessment and Medical Management
409
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
409
